Roche on Monday joined AstraZeneca in withdrawing cancer immunotherapies from U.S. use for bladder cancer that has already been treated with platinum-based chemotherapy, after follow-up studies failed to meet goals. Basel-based Roche said in a statement it was withdrawing the U.S. indication for Tecentriq, with some $3 billion in 2020 sales, in prior-platinum treated metastatic urothelial carcinoma. In February, AstraZeneca announced a similar move for its $2 billion-per-year drug Imfinzi.